Analyst views promise of Amneal's IPX-203 in Parkinson's disease

US drugmaker Amneal Pharmaceuticals (NYSE: AMRX) has recently announced that its pipeline product IPX-203 (carbidopa + levodopa, (CD/LD)) achieved key primary and secondary endpoints in the pivotal Phase III RISE-PD clinical trial for patients with Parkinson’s disease (PD) who experience motor fluctuations.

Levodopa’s short half-life makes dosing difficult to manage and the treatment is often associated with dyskinesia and the medicine’s wearing-off episodes. The market for new products aimed at controlling motor fluctuations holds great potential, says GlobalData, a leading data and analytics company.

“Levodopa has been the gold standard of care for patients with PD for over 50 years. However, the decline in efficacy of levodopa and the emergence of motor fluctuations after a few years of its use remains a major challenge for physicians and patients,” commented GlobalData’s pharma analyst Christie Wong.